Breast Cancer Edition: Top Headlines for Week of November 7, 2022

In this episode, data show ‘critical need’ for universal genetic testing; patients with inflammatory breast cancer at high risk for brain metastases; palbociclib fails to benefit breast cancer subgroup and more.

Read the full coverage here:

Data show ‘critical need’ for universal genetic testing of patients with breast cancer

Patients with inflammatory breast cancer at high risk for brain metastases

Palbociclib fails to benefit breast cancer subgroup, yielding lessons for future research

Low-dose aspirin does not reduce breast cancer risk

Interventions improve cancer screening rates among women in rural areas

References:

Cairat M, et al. Abstract 1840. Presented at: World Cancer Congress; Oct. 18-20, 2022; Geneva.

DeMichele A, et al. Adjuvant palbociclib for ER+ breast cancer (PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13): A preplanned analysis of the stage IIA cohort. Presented at: ASCO Plenary Series; Oct. 18, 2022.

Paskett ED, et al. Abstract 1959. Presented at: World Cancer Congress; Oct. 18-20, 2022; Geneva.

Warren LEG, et al. Cancer. 2022;doi:10.1002/cncr.34441.

Whitworth PW, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.32787.